Skip to main content
Erschienen in: Tumor Biology 12/2016

08.10.2016 | Original Article

A promising prediction model for survival in gallbladder carcinoma patients: pretreatment prognostic nutrient index

verfasst von: Yan Deng, Qing Pang, Jian-Bin Bi, Xing Zhang, Ling-qiang Zhang, Yan-Yan Zhou, Run-Chen Miao, Wei Chen, Kai Qu, Chang Liu

Erschienen in: Tumor Biology | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

The pretreatment nutritional and immunological status play indispensable roles in predicting the outcome of patients with various types of malignancies. The aim of the study was to investigate whether preoperative prognostic nutritional index (PNI), which simply accounts for nutritional and immunological status, was associated with overall survival (OS) in patients with gallbladder carcinoma (GBC). The retrospective study included a total of 315 GBC patients after surgery between 2002 and 2012. PNI was calculated according to the following formula: 10× serum albumin (g/dl) +0.005× total lymphocyte count (per mm3). A receiver operating characteristic (ROC) curve for survival prediction was plotted to verify the optimal cutoff value for LMR, which was set at 46.14. According the value, patients were categorized into two different groups, namely high-PNI group (n = 133) and low-PNI group (n = 182). The univariate and multivariate Cox regression models were used to identify the independent prognostic factors. The results showed that low pretreatment PNI value was significantly associated with elderly age, partial surgery procedure, and advanced tumor status such as tumor stage, node stage, and tumor-node-metastasis stage (P < 0.05). The low-PNI group had a worse OS compare with the high-PNI group (P < 0.05). Via univariate and multivariate analyses, pretreatment PNI was identified as an independent prognostic factor for OS [HR: 0.613; 95%CI: 0.448–0.838; P < 0.001]. Subgroup analyses further revealed that PNI was significantly associated with postoperative OS independent of tumor node metastasis stage and surgical procedure. In conclusion, pretreatment PNI might serve as an effective predictor to evaluate prognosis of GBC patients after surgery. Based on the findings, PNI, characterized with accessibility, objectivity and noninvasiveness, should be included in the routine assessment of GBC.
Literatur
4.
Zurück zum Zitat Poojary SS, Mishra G, Gupta S, Shrivastav BR, Tiwari PK. Dysfunction of subtelomeric methylation and telomere length in gallstone disease and gallbladder cancer patients of North Central India. J Hepatobiliary Pancreat Sci. 2016. doi:10.1002/jhbp.332.PubMed Poojary SS, Mishra G, Gupta S, Shrivastav BR, Tiwari PK. Dysfunction of subtelomeric methylation and telomere length in gallstone disease and gallbladder cancer patients of North Central India. J Hepatobiliary Pancreat Sci. 2016. doi:10.​1002/​jhbp.​332.PubMed
6.
Zurück zum Zitat Yeh CN, Jan YY, Chao TC, Chen MF. Laparoscopic cholecystectomy for polypoid lesions of the gallbladder: a clinicopathologic study. Surg Laparosc Endosc Percutan Tech. 2001;11(3):176–81.CrossRefPubMed Yeh CN, Jan YY, Chao TC, Chen MF. Laparoscopic cholecystectomy for polypoid lesions of the gallbladder: a clinicopathologic study. Surg Laparosc Endosc Percutan Tech. 2001;11(3):176–81.CrossRefPubMed
8.
Zurück zum Zitat Schwegler I, von Holzen A, Gutzwiller JP, Schlumpf R, Muhlebach S, Stanga Z. Nutritional risk is a clinical predictor of postoperative mortality and morbidity in surgery for colorectal cancer. Br J Surg. 2010;97(1):92–7. doi:10.1002/bjs.6805. Schwegler I, von Holzen A, Gutzwiller JP, Schlumpf R, Muhlebach S, Stanga Z. Nutritional risk is a clinical predictor of postoperative mortality and morbidity in surgery for colorectal cancer. Br J Surg. 2010;97(1):92–7. doi:10.​1002/​bjs.​6805.
10.
Zurück zum Zitat Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. 1984;85(9):1001–5.PubMed Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. 1984;85(9):1001–5.PubMed
11.
Zurück zum Zitat Jian-Hui C, Iskandar EA, Cai SI, Chen CQ, Wu H, JB X, et al. Significance of Onodera’s prognostic nutritional index in patients with colorectal cancer: a large cohort study in a single Chinese institution. Tumour Biol. 2015. doi:10.1007/s13277-015-4008-8.PubMedPubMedCentral Jian-Hui C, Iskandar EA, Cai SI, Chen CQ, Wu H, JB X, et al. Significance of Onodera’s prognostic nutritional index in patients with colorectal cancer: a large cohort study in a single Chinese institution. Tumour Biol. 2015. doi:10.​1007/​s13277-015-4008-8.PubMedPubMedCentral
15.
Zurück zum Zitat Shimizu K, Okita R, Saisho S, Maeda A, Nojima Y, Nakata M. Preoperative neutrophil/lymphocyte ratio and prognostic nutritional index predict survival in patients with non-small cell lung cancer. World Journal of Surgical Oncology. 2015;13(1). doi:10.1186/s12957-015-0710-7. Shimizu K, Okita R, Saisho S, Maeda A, Nojima Y, Nakata M. Preoperative neutrophil/lymphocyte ratio and prognostic nutritional index predict survival in patients with non-small cell lung cancer. World Journal of Surgical Oncology. 2015;13(1). doi:10.​1186/​s12957-015-0710-7.
16.
Zurück zum Zitat Chen KL, Liu YH, Li WY, Chen J, YK G, Geng QR, et al. The prognostic nutritional index predicts survival for patients with extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol. 2015;94(8):1389–400. doi:10.1007/s00277-015-2361-8.CrossRefPubMed Chen KL, Liu YH, Li WY, Chen J, YK G, Geng QR, et al. The prognostic nutritional index predicts survival for patients with extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol. 2015;94(8):1389–400. doi:10.​1007/​s00277-015-2361-8.CrossRefPubMed
17.
18.
Zurück zum Zitat Jeon HG, Choi DK, Sung HH, Jeong BC, Seo SI, Jeon SS, et al. Preoperative prognostic nutritional index is a significant predictor of survival in renal cell carcinoma patients undergoing nephrectomy. Annals ofSurgical Oncology. 2015. doi:10.1245/s10434-015-4614-0. Jeon HG, Choi DK, Sung HH, Jeong BC, Seo SI, Jeon SS, et al. Preoperative prognostic nutritional index is a significant predictor of survival in renal cell carcinoma patients undergoing nephrectomy. Annals ofSurgical Oncology. 2015. doi:10.​1245/​s10434-015-4614-0.
19.
Zurück zum Zitat Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DS, et al. A comparison of inflammation-based prognostic scores in patients with cancer: a Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47(17):2633–41. doi:10.1016/j.ejca.2011.03.028.CrossRefPubMed Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DS, et al. A comparison of inflammation-based prognostic scores in patients with cancer: a Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47(17):2633–41. doi:10.​1016/​j.​ejca.​2011.​03.​028.CrossRefPubMed
22.
Zurück zum Zitat Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, et al. Prognostic factors of patients with advanced gallbladder carcinoma following aggressive surgical resection. J Gastrointest Surg. 2011;15(6):1007–16. doi:10.1007/s11605-011-1479-9.CrossRefPubMed Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, et al. Prognostic factors of patients with advanced gallbladder carcinoma following aggressive surgical resection. J Gastrointest Surg. 2011;15(6):1007–16. doi:10.​1007/​s11605-011-1479-9.CrossRefPubMed
26.
27.
Zurück zum Zitat D’Hondt M, Lapointe R, Benamira Z, Pottel H, Plasse M, Letourneau R, et al. Carcinoma of the gallbladder: patterns of presentation, prognostic factors and survival rate—an 11-year single centre experience. Eur J Surg Oncol. 2013;39(6):548–53. doi:10.1016/j.ejso.2013.02.010.CrossRefPubMed D’Hondt M, Lapointe R, Benamira Z, Pottel H, Plasse M, Letourneau R, et al. Carcinoma of the gallbladder: patterns of presentation, prognostic factors and survival rate—an 11-year single centre experience. Eur J Surg Oncol. 2013;39(6):548–53. doi:10.​1016/​j.​ejso.​2013.​02.​010.CrossRefPubMed
30.
34.
35.
Zurück zum Zitat Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Investig. 2003;32(3):201–15.CrossRef Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Investig. 2003;32(3):201–15.CrossRef
36.
Zurück zum Zitat Suzana S, Boon PC, Chan PP, Normah CD. Malnutrition risk and its association with appetite, functional and psychosocial status among elderly Malays in an agricultural settlement. Malays J Nutr. 2013;19(1):65–75.PubMed Suzana S, Boon PC, Chan PP, Normah CD. Malnutrition risk and its association with appetite, functional and psychosocial status among elderly Malays in an agricultural settlement. Malays J Nutr. 2013;19(1):65–75.PubMed
39.
Zurück zum Zitat Yamashita K, Ushiku H, Katada N, Hosoda K, Moriya H, Mieno H, et al. Reduced preoperative serum albumin and absence of peritoneal dissemination may be predictive factors for long-term survival with advanced gastric cancer with positive cytology test. Eur J Surg Oncol. 2015;41(10):1324–32. doi:10.1016/j.ejso.2015.05.021.CrossRefPubMed Yamashita K, Ushiku H, Katada N, Hosoda K, Moriya H, Mieno H, et al. Reduced preoperative serum albumin and absence of peritoneal dissemination may be predictive factors for long-term survival with advanced gastric cancer with positive cytology test. Eur J Surg Oncol. 2015;41(10):1324–32. doi:10.​1016/​j.​ejso.​2015.​05.​021.CrossRefPubMed
40.
Zurück zum Zitat Laursen I, Briand P, Lykkesfeldt AE. Serum albumin as a modulator on growth of the human breast cancer cell line, MCF-7. Anticancer Res. 1990;10(2 A):343–51.PubMed Laursen I, Briand P, Lykkesfeldt AE. Serum albumin as a modulator on growth of the human breast cancer cell line, MCF-7. Anticancer Res. 1990;10(2 A):343–51.PubMed
41.
Zurück zum Zitat Sonnenschein C, Soto AM, Michaelson CL. Human serum albumin shares the properties of estrocolyone-I, the inhibitor of the proliferation of estrogen-target cells. J Steroid Biochem Mol Biol. 1996;59(2):147–54.CrossRefPubMed Sonnenschein C, Soto AM, Michaelson CL. Human serum albumin shares the properties of estrocolyone-I, the inhibitor of the proliferation of estrogen-target cells. J Steroid Biochem Mol Biol. 1996;59(2):147–54.CrossRefPubMed
Metadaten
Titel
A promising prediction model for survival in gallbladder carcinoma patients: pretreatment prognostic nutrient index
verfasst von
Yan Deng
Qing Pang
Jian-Bin Bi
Xing Zhang
Ling-qiang Zhang
Yan-Yan Zhou
Run-Chen Miao
Wei Chen
Kai Qu
Chang Liu
Publikationsdatum
08.10.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 12/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5396-0

Weitere Artikel der Ausgabe 12/2016

Tumor Biology 12/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.